Revenue
18.3 million Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA
2022 Q2 · Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA
Exact inputs and evidence
- Revenue: 18346000 Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA Source
Fundies. English
Redhill Biopharma Ltd.
EDGARAnnual consolidated revenue for 2025: about Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 286K, using the latest reported figures.
Latest quarter
Operating margin
-49.92%
2022 Q2 · %
Operating cash flow
-16.6 million Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA
2022 Q2 · Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA
Exact inputs and evidence
- Operating Cash Flow: -16581000 Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA Source
Free cash flow
-16.7 million Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA
2022 Q2 · Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA
- Cash and cash equivalents
- Not available
- Long-term debt including current maturities
- Not available
- Shares outstanding
- Not available
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-07.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2025-12-31
- Operating income: 3 of 11 periods available· newest 2025-12-31
- net income: No compatible figures in this window
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2025-12-31
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
- long term debt: No compatible figures in this window
- shares outstanding: No compatible figures in this window
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Operating cash flow
−Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 282,000Prior period
−Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9.37 million
–
Current period
−Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9.65 million
–
Exact inputs and evidence
-9651000 − -9369000 = -282000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ
-9369000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-9651000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-44.4%Prior period
Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9,000
–
Current period
Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 5,000
–
Exact inputs and evidence
5000 − 9000 = -4000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ
9000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ · 2024-01-01 – 2024-12-31
Inspect prior input Prior source5000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Net income.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 286,000 100% of revenue
- Operating costs Derived Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 8.23 million 2,877% of revenue
- Operating income −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 7.94 million −2,777% of revenue
- Tax, interest and other Derived Unavailable An input is unavailable.
- Net income Unavailable An input is unavailable.
Cash
- Operating cash flow −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9.65 million −3,374% of revenue
- Capital expenditure Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 5,000 1.7% of revenue
- Free cash flow Derived −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9.66 million −3,376% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2025 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2025 2025-01-01 – 2025-12-31 | 286000 | 8228000 Derived | -7942000 | Unavailable | Unavailable | -9656000 Derived | Source
|
Amounts are exact, in Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 286K 2025
Values and sources
| Period | Series | Value(Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ) | Source evidence |
|---|---|---|---|
| 2025 | Revenue | 286000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -2,776.9% 2025
Free cash flow margin -3,376.2% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Operating margin | -2,776.9% |
|
| 2025-12-31 | Net margin | Not reported |
|
| 2025 | Free cash flow margin | -3,376.2% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ -9.7M 2025
Values and sources
| Period | Series | Value(Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ) | Source evidence |
|---|---|---|---|
| 2025 | Operating cash flow | -9651000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ -9.7M 2025
Values and sources
| Period | Series | Value(Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ) | Source evidence |
|---|---|---|---|
| 2025 | Free cash flow | -9656000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025-12-31 | Liabilities / assets | Not reported | No source recorded |
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025-12-31 | Current assets / current liabilities | Not reported | No source recorded |
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | Unavailable Not reported for this period. | −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 35.82 million Exact valueExact value: -35820000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 2023-01-01 – 2023-12-31: -35820000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 11,000 Exact valueExact value: 11000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 2023-01-01 – 2023-12-31: 11000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Inspect Capital Expenditure Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 35.83 million Calculation and evidence-35820000 − 11000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Exact free cash flow: -35831000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | Unavailable Not reported for this period. | −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9.37 million Exact valueExact value: -9369000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 2024-01-01 – 2024-12-31: -9369000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9,000 Exact valueExact value: 9000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 2024-01-01 – 2024-12-31: 9000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Inspect Capital Expenditure Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9.38 million Calculation and evidence-9369000 − 9000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Exact free cash flow: -9378000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | Unavailable Not reported for this period. | −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9.65 million Exact valueExact value: -9651000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 2025-01-01 – 2025-12-31: -9651000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 5,000 Exact valueExact value: 5000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 2025-01-01 – 2025-12-31: 5000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Inspect Capital Expenditure Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ 9.66 million Calculation and evidence-9651000 − 5000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ Exact free cash flow: -9656000 Unit_Standard_USD_8DqGPFSgIkaNYn5AaL9dlQ
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
799 filings · 1,828 latest values · 1,828 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001553846, 1553846, RDHL, edgar:1553846
Also known as REDHILL BIOPHARMA LTD., RedHill Biopharma Ltd., Redhill Biopharma Ltd.